Unadjusted logistic regression analyses showed that the risk of MetS increased as chemerin participants with high levels of serum chemerin are more likely to have dyslipidemia with low HDL-C (OR: 15.12, 95% CI: 1.58–144.5) after adjustment for age, gender, and BMI. This evidence concerns the gene RARRES2 and metabolic syndrome.